SCHEMBL434570

SCHEMBL434570

Cc1cc2ccccn2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.54
ABL1 P00519 1/20 0.54
MAPK8 P45983 1/20 0.54
CSNK1A1 P48729 1/20 0.54
CDK7 P50613 1/20 0.54
TYRO3 Q06418 1/20 0.54
LRRK2 Q5S007 1/20 0.54
AURKB Q96GD4 1/20 0.54
CLK4 Q9HAZ1 1/20 0.54
PIM2 Q9P1W9 1/20 0.54
DYRK1B Q9Y463 1/20 0.54
NPC1 O15118 5/20 0.50
RAB9A P51151 5/20 0.50
MAPT P10636 5/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 10/20 0.46
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10743642 0.76 RAB9A (0.41) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL10129496 0.75 MAP4K4 (0.47) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL651412 0.75 MAP4K4 (0.47) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL4899669 0.75 CCR1 (0.52) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL7381473 0.75 TP53 (0.62) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL23535657 0.74 NPC1 (0.46) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL14809152 0.74 MAP4K4 (0.46) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL2849283 0.74 MAP4K4 (0.46) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL1269053 0.74 MAP4K4 (0.50) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL13569111 0.74 MAP4K4 (0.46) MAP4K4ABL1MAPK8CSNK1A1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 US claimed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
US-12336537-B2 Fungicidal compositions SYNGENTA CROP PROTECTION AG (CH) 2025-06-24 US disclosed
US-12024510-B2 Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same PI INDUSTRIES LTD. (IN) 2024-07-02 US disclosed
US-12018024-B2 Compounds and compositions for the treatment of cryptosporidiosis NOVARTIS AG (CH) 2024-06-25 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
WO-2024108147-A1 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-05-23 WO disclosed
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 WO disclosed
WO-2024059845-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 WO disclosed
EP-0191401-B1 NOVEL ANTIALLERGIC AGENTS AND PROCESS FOR THEIR PREPARATION KYORIN PHARMACEUTICAL CO., LTD. (JP) 1991-03-06 EP disclosed
US-4923871-A ANTITUMOR KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1990-05-08 US disclosed
EP-0270926-A2 Agents promoting the activity of some antitumor agents and methods for their production KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1988-06-15 EP disclosed
US-4680398-A Pyrazolo[1,5-a]pyridines and benzimidazoles, useful as antiallergic agents KYORIN PHARMACEUTICAL CO., LTD. (JP) 1987-07-14 US disclosed
EP-0121197-B1 PYRAZOLOPYRIDINE DERIVATIVES, THERAPEUTIC COMPOSITIONS COMPRISING SAME, AND PROCESS THEREOF KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1986-11-20 EP disclosed
EP-0191401-A2 Novel antiallergic agents and process for their preparation KYORIN PHARMACEUTICAL CO., LTD. (JP) 1986-08-20 EP disclosed
US-4559402-A ANTICOAGULANTS KYORIN SEIYAKI KABUSHIKI KAISHA (JP) 1985-12-17 US disclosed
EP-0121197-A1 Pyrazolopyridine derivatives, therapeutic compositions comprising same, and process thereof KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1984-10-10 EP disclosed
US-4097483-A HYPOTENSIVE AND ANTISPASMODIC AGENT KYORIN PHARMACEUTICAL CO., LTD. (JA) 1978-06-27 US disclosed
US-4028370-A SMOOTH MUSCLE RELAXANTS, CEREBRAL AND CORONARY DILATORS, HYPOTENSIVE AGENTS KYORIN PHARMACEUTICAL CO., LTD. (JA) 1977-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018024-B2 Compounds and compositions for the treatment of cryptosporidiosis SLC10A2, SI, SLC10A1 MAP4K4 2080/4885ABL1 562/4885MAPK8 3091/4885
US-12024510-B2 Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same DDT, QDPR, CYP1A1 MAP4K4 1130/4885ABL1 727/4885MAPK8 4165/4885
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP MAP4K4 3893/4885ABL1 3613/4885MAPK8 4017/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH MAP4K4 4353/4885ABL1 4113/4885MAPK8 4177/4885
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC1 MAP4K4 3369/4885ABL1 4510/4885MAPK8 3290/4885
US-12336537-B2 Fungicidal compositions CYP51A1, CYP4X1, CYP1B1 MAP4K4 4401/4885ABL1 1254/4885MAPK8 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.